Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

OSI-420

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
BackgroundErlotinib shows large inter-patient pharmacokinetic variability, but the impact of early drug exposure and genetic… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Although there have been several reports in which central nervous system (CNS) metastases of non-small cell lung… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic glioma (AG), and (b) nonprogressive… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2010
2010
INTRODUCTION Although erlotinib, an orally active and selective tyrosine kinase inhibitor of epidermal growth factor receptor, is… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Purpose: To report cerebrospinal fluid (CSF) penetration of erlotinib and its metabolite OSI-420. Experimental Design… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
2007
2007
An accurate and precise method was developed using HPLC-MS/MS to quantify erlotinib (OSI-774) and its O-desmethyl metabolite, OSI… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Purpose: To compare the pharmacokinetic variables of erlotinib in current smokers with nonsmokers after receiving a single oral… Expand
  • figure 2
  • table 2
  • figure 3
  • figure 4
Is this relevant?
2005
2005
A new method was developed and validated for quantitating OSI-774 and its metabolite OSI-420 in human plasma. Sample preparation… Expand
Is this relevant?
2003
2003
A new simple and specific method was developed and validated for the quantitative determination of OSI-774 (Tarceva, Erlotinib… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
PURPOSE To assess the feasibility of administering OSI-774, to recommend a dose on a protracted, continuous daily schedule, to… Expand
Is this relevant?